Propolis effects on cholesterol levels in type 2 diabetes patients
The Effect of Propolis Administration on Low Density Lipoprotein and High Density Lipoprotein in Diabetic Type 2 Patients in Central Jakarta
This study is testing if taking propolis can help lower bad cholesterol and raise good cholesterol in people with type 2 diabetes.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 35 Years to 59 Years |
| Sex | All |
| Sponsor | Indonesia University Academic / other |
| Locations | 1 site (Jakarta) |
| Trial ID | NCT06903546 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates whether propolis administration can alter Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) cholesterol levels in patients with type 2 diabetes. Participants will receive either propolis or a placebo twice daily for eight weeks, with regular check-ups and blood tests to monitor changes in cholesterol levels. The study employs a randomized, double-blind design to ensure unbiased results. Data collected will include participants' medical history, dietary intake, and physical activity levels.
Who should consider this trial
Good fit: Ideal candidates are adults with controlled type 2 diabetes, a BMI between 23-35, and currently on anti-cholesterol therapy.
Not a fit: Patients using insulin or GLP-1 receptor agonists, those with a history of bee product allergies, or individuals with significant liver or kidney dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural treatment option to improve cholesterol levels in patients with type 2 diabetes.
How similar studies have performed: While the use of propolis in managing cholesterol levels is not widely studied, similar natural interventions have shown promise in other contexts, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Controlled Diabetes Mellitus type 2 with HbA1c \<7.5% * BMI 23-35 kg/m2 * On anti-cholesterol therapy Exclusion Criteria: * Using injection therapy (insulin or GLP-1 RA) * History of bees product allergy * Active smoker * Consuming alcohol * Altered liver (ALT\>35 IU/L) and kidney (eGFR\<90 mL/min) function * Pregnant and breastfeeding women * History of cardiovascular disease (heart attack, stroke)
Where this trial is running
Jakarta
- University of Indonesia Faculty of Biomedical Science — Jakarta, Indonesia (Recruiting)
Study contacts
- Principal investigator: Dwirini R Gunarti, Biomed Science — Indonesia University
- Study coordinator: Dwirini R Gunarti, Biomed Science
- Email: rinairet@gmail.com
- Phone: +62 8118382301
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.